CanSino's COVID-19 Vaccine Was Just Approved for Limited Use in China. Here's What Investors Should Know.
Despite a worldwide race to develop a COVID-19 vaccine, China's CanSino Biologics (SEHK: 6185) didn't make huge headlines when it announced last week that its COVID-19 vaccine candidate had been approved for widespread use among members of the Chinese military. Between the vaccine's small population of eligible recipients, its limited efficacy, and its intense side effects, nobody seems to be clamoring to license it for manufacturing outside China.
CanSino's stock price has also remained shockingly unperturbed by the company's breakthrough. Its highs from May show no sign of returning, and its trading volume remains nearly flat. Nonetheless, after the stock's triple-digit growth this year so far, investors are right to be fearful of missing out on future returns with CanSino or another COVID-19 vaccine stock.
Image source: Getty Images.
Source Fool.com
